HeartSciences Inc.

HeartSciences Inc. has entered into an Agreement and Plan of Merger with Fortitude Mining Holdings, Inc. and its subsidiary, Fortitude Mining HoldCo, LLC. HeartSciences' subsidiary will merge with Fortitude, making HeartSciences the sole managing member of the surviving entity. In connection with this transaction, HeartSciences' CEO and Chairman, Andrew Simpson, had his employment agreement amended, and he was granted 425,000 restricted shares as a retention bonus, which will vest over one year post-closing, subject to continuous employment. The equity award is exempt from registration.

HeartSciences Inc. has entered into a definitive merger agreement with Fortitude Mining Holdings, Inc. The all-stock transaction will result in the combined company operating under the Fortitude brand, led by Fortitude's management, and listed on Nasdaq under the ticker TUDE. Fortitude, a Zcash mining platform, reported $90 million in gross revenue and $20 million in Adjusted EBITDA for full year 2025. HeartSciences' CEO stated the merger allows them to advance their medical technology with greater focus, free from constant capital raising, aiming to maximize shareholder value.

HeartSciences Inc. (HSCS), an AI-powered medical technology company, has entered into a definitive merger agreement with Fortitude Mining Holdings, Inc., a Zcash mining platform wholly-owned by Digital Currency Group (DCG). The all-stock transaction will result in the combined entity operating under the Fortitude brand and trading on Nasdaq under the ticker "TUDE". The merger is expected to close in the second half of 2026, with DCG anticipated to own approximately 95% of the combined company. HeartSciences' current CEO will continue to lead its healthcare business unit.

HeartSciences Inc. announced the European Patent Office granted European Patent No. EP4252651, titled "Electrocardiogram-Based Assessment of Diastolic Function." This patent covers machine-learning models and methods for computing quantitative estimates of echocardiogram parameters indicative of diastolic function using ECG data. The patent became effective as a Unitary Patent on April 29, 2026, providing coverage in 19 European countries and expanding the company's intellectual property portfolio to over 45 granted patents.

HeartSciences Inc. announced a commercial agreement with North Shore Health for the deployment of its MyoVista Insights platform. This significant deal marks the first deployment within the Cibolo Rural Health Networks, which previously endorsed MyoVista Insights for its 127 independent hospitals. The agreement is a SaaS-based revenue deployment, supporting HeartSciences' commercial rollout and demonstrating potential for broader adoption across the Cibolo network. The platform aims to enhance workflow efficiency, EHR interoperability, and integrate AI-ECG algorithms into clinical workflows.

HeartSciences Inc. announced a commercial agreement with St. Vincent Health to deploy its MyoVista Insights™ platform. This marks the company's first mainstream revenue-generating deployment for the SaaS-based ECG management platform, building on previous early adopter installations. The MyoVista Insights platform is designed to enhance workflow efficiency, provide EHR interoperability, and integrate AI-ECG algorithms into clinical workflows. HeartSciences anticipates securing additional commercial agreements in the coming quarters.

HeartSciences Inc. is reminding shareholders to vote ahead of its upcoming Annual Meeting, scheduled virtually for Thursday, April 30, 2026, at 10:00 a.m. Eastern Time. Shareholders of record as of March 6, 2026, are entitled to participate and vote. The company encourages all shareholders to submit their proxy card online via Equiniti's website, www.voteproxy.com, by April 29, 2026, at 11:59 p.m. ET.